Cell Marque Portfolio

BCL6 (GI191E/A8)

Mouse Monoclonal


BCL6 is a transcriptional regulator gene which codes for a 706-amino-acid nuclear zinc finger protein.1 In normal tissue these antibodies have strong nuclear staining for a subset of B-lymphocytes, mostly located in germinal centers (GC).2 BCL6 antibodies stain malignant cells in follicular lymphoma,3 diffuse large B-cell lymphomas,4 Burkitt lymphoma,4 classical Hodgkin lymphoma,5 as well as majority of tumor cells in nodular lymphocyte predominant Hodgkin lymphoma.6  BCL6 expression has been also seen in anaplastic large cell lymphomas (ALCL).7

BCL6 is protected by U.S. patents 6,174,997 and 6,783,94 (Cancer Genetics, Inc.)

Specialties: Hematopathology

Specifications


  • Reactivity: paraffin
  • Visualization: nuclear
  • Control: tonsil
  • Isotype: IgG1
  • Dilution Range: 1:100-1:500*

Protocols


  • Cell Marque HiDef
    T-PC/10-30minAb/HiDef/Perm Red
  • Cell Marque HiDef
    T-PC/10-30minAb/HiDef/DAB
  • Ventana ultraView
    UV/CC1S/32min @ 37°C

Download an IFU

Select revision:


Keycode Specific IFU

Keycode:
Select prefix.
Please verify your keycode and try again. If problems presist contact Customer Service
Enter keycode.
Please verify your keycode and try again. If problems presist contact Customer Service

Some products may have special labeling requirements in the United States.

Are you located in the U.S.?



*Note: IFUs with the prefix RUO or ASR are only available for download in English.


Click here to learn about keycodes

Download SDS

References


  1. Falini B, et al. Bcl-6 protein expression in normal and neoplastic lymphoid tissues. Ann Oncol. 1997; 2: 101-4.
  2. Aukema SM, et al. Double-hit B-cell lymphomas. Blood 2011; 117:2319-31.
  3. Dogan A, et al. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol. 2000; 24:846-52.
  4. Carbone A, et al. B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology. Hum Pathol. 2010; 41:621-31.
  5. Bai M, et al. B-cell differentiation immunophenotypes in classical Hodgkin lymphomas. Leuk Lymphoma. 2006; 47:495-501.
  6. Carbone A, et al. Expression of BCL-6 protein and CD138/syndecan-1 as B-cell markers in Hodgkin's disease. Int J Biol Markers 1999; 14:144-8.
  7. Saglam A, et al. Immunohistochemical expression of Mum-1, Oct-2 and Bcl-6 in systemic anaplastic large cell lymphomas. Tumori. 2011; 97:634-8.

Last updated: 2017-04-11 15:07:07

BCL6
BCL6 (GI19E/A8) on tonsil, germinal centers.

Mouse over to zoom, use scroll wheel to zoom in/out

Tap image once to activate zoom lens


Specifications


  • Reactivity: paraffin
  • Visualization: nuclear
  • Control: tonsil
  • Isotype: IgG1
  • Dilution Range: 1:100-1:500*

Protocols


  • Cell Marque HiDef
    T-PC/10-30minAb/HiDef/Perm Red
  • Cell Marque HiDef
    T-PC/10-30minAb/HiDef/DAB
  • Ventana ultraView
    UV/CC1S/32min @ 37°C

References


  1. Falini B, et al. Bcl-6 protein expression in normal and neoplastic lymphoid tissues. Ann Oncol. 1997; 2: 101-4.
  2. Aukema SM, et al. Double-hit B-cell lymphomas. Blood 2011; 117:2319-31.
  3. Dogan A, et al. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol. 2000; 24:846-52.
  4. Carbone A, et al. B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology. Hum Pathol. 2010; 41:621-31.
  5. Bai M, et al. B-cell differentiation immunophenotypes in classical Hodgkin lymphomas. Leuk Lymphoma. 2006; 47:495-501.
  6. Carbone A, et al. Expression of BCL-6 protein and CD138/syndecan-1 as B-cell markers in Hodgkin's disease. Int J Biol Markers 1999; 14:144-8.
  7. Saglam A, et al. Immunohistochemical expression of Mum-1, Oct-2 and Bcl-6 in systemic anaplastic large cell lymphomas. Tumori. 2011; 97:634-8.

Download an IFU

Select revision:


Download SDS


Ordering Information

For in vitro diagnostic (IVD) use in USA

DescriptionCat. No.
0.1 ml, concentrate 227M-94
0.5 ml, concentrate 227M-95
1 ml, concentrate 227M-96
1 ml, predilute 227M-97
7 ml, predilute 227M-98
25 ml, predilute 227M-90

For in vitro diagnostic (IVD) use in Canada

DescriptionCat. No.
0.1 ml, concentrate 227M-94
0.5 ml, concentrate 227M-95
1 ml, concentrate 227M-96
1 ml, predilute 227M-97
7 ml, predilute 227M-98
25 ml, predilute 227M-90

For in vitro diagnostic (IVD) use in the EU

DescriptionCat. No.
0.1 ml, concentrate 227M-94
0.5 ml, concentrate 227M-95
1 ml, concentrate 227M-96
1 ml, predilute 227M-97
7 ml, predilute 227M-98
25 ml, predilute 227M-90

For research use only (RUO) in Japan

DescriptionCat. No.
0.1 ml, concentrate 227M-94-RUO
0.5 ml, concentrate 227M-95-RUO
1 ml, concentrate 227M-96-RUO
1 ml, predilute 227M-97-RUO
7 ml, predilute 227M-98-RUO
25 ml, predilute 227M-90-RUO

Specifications


  • Reactivity: paraffin
  • Visualization: nuclear
  • Control: tonsil
  • Isotype: IgG1
  • Dilution Range: 1:100-1:500*

Protocols


  • Cell Marque HiDef
    T-PC/10-30minAb/HiDef/Perm Red
  • Cell Marque HiDef
    T-PC/10-30minAb/HiDef/DAB
  • Ventana ultraView
    UV/CC1S/32min @ 37°C

Download an IFU

Select revision:


Keycode Specific IFU

Keycode:
Select prefix.
Please verify your keycode and try again. If problems presist contact Customer Service
Enter keycode.
Please verify your keycode and try again. If problems presist contact Customer Service

Some products may have special labeling requirements in the United States.

Are you located in the U.S.?


*Note: IFUs with the prefix RUO or ASR are only available for download in English.



Click here to learn about keycodes

Download SDS

References


  1. Falini B, et al. Bcl-6 protein expression in normal and neoplastic lymphoid tissues. Ann Oncol. 1997; 2: 101-4.
  2. Aukema SM, et al. Double-hit B-cell lymphomas. Blood 2011; 117:2319-31.
  3. Dogan A, et al. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol. 2000; 24:846-52.
  4. Carbone A, et al. B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology. Hum Pathol. 2010; 41:621-31.
  5. Bai M, et al. B-cell differentiation immunophenotypes in classical Hodgkin lymphomas. Leuk Lymphoma. 2006; 47:495-501.
  6. Carbone A, et al. Expression of BCL-6 protein and CD138/syndecan-1 as B-cell markers in Hodgkin's disease. Int J Biol Markers 1999; 14:144-8.
  7. Saglam A, et al. Immunohistochemical expression of Mum-1, Oct-2 and Bcl-6 in systemic anaplastic large cell lymphomas. Tumori. 2011; 97:634-8.
Request More Information